➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
AstraZeneca
Express Scripts
Moodys
Johnson and Johnson

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,193,685

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,193,685 protect, and when does it expire?

Patent 9,193,685 protects ARISTADA and is included in one NDA.

This patent has eleven patent family members in seven countries.

Summary for Patent: 9,193,685
Title:Pharmaceutical compositions having improved storage stability
Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
Inventor(s): Perry; Jason M. (Cambridge, MA), Deaver; Daniel R. (Franklin, MA), Hickey; Magali B. (Westwood, MA), Remenar; Julius F. (Framingham, MA), Vandiver; Jennifer (Arlington, MA), Palmieri, Jr.; Michael J. (Hopkington, MA), Pan; Zhengzheng (Arlington, MA)
Assignee: ALKERMES PHARMA IRELAND LIMITED (Dublin, IE)
Application Number:14/031,842
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 9,193,685

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-001 Oct 5, 2015 RX Yes No   Start Trial   Start Trial Y TREATMENT OF SCHIZOPHRENIA   Start Trial
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-002 Oct 5, 2015 RX Yes No   Start Trial   Start Trial Y TREATMENT OF SCHIZOPHRENIA   Start Trial
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-003 Oct 5, 2015 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF SCHIZOPHRENIA   Start Trial
Alkermes Inc ARISTADA aripiprazole lauroxil SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207533-004 Jun 5, 2017 RX Yes No   Start Trial   Start Trial Y TREATMENT OF SCHIZOPHRENIA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,193,685

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013349388   Start Trial
Canada 2885196   Start Trial
European Patent Office 2897592   Start Trial
Hong Kong 1210033   Start Trial
Japan 2015529237   Start Trial
Japan 2018090629   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
McKinsey
Harvard Business School
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.